Nanoviricides Inc (NNVC)

$1.23 +0.01 (0.82%)
Market Cap 22.14M
Revenue (ttm) 0.00
Net Income (ttm) -9.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 337,400
Avg Vol 324,624
Day's Range N/A - N/A
Shares Out 18.00M
Stochastic %K 73%
Beta 1.16
Analysts Strong Sell
Price Target $7.00

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gumm...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 937 6137
Address:
1 Controls Drive, Shelton, United States
Love1010
Love1010 Dec. 6 at 1:43 PM
$NNVC look at all the new pumpers out here! Beware! They're trying to sell shares off to you!
0 · Reply
IPOwizzard
IPOwizzard Dec. 5 at 8:03 PM
$NNVC nom
0 · Reply
CameoBrien
CameoBrien Dec. 5 at 5:58 PM
$NNVC still upside
0 · Reply
CameoBrien
CameoBrien Dec. 5 at 3:44 PM
$NNVC bam
0 · Reply
NoHandOutz
NoHandOutz Dec. 5 at 3:09 PM
$NNVC give it some time. Big boys scaling
0 · Reply
IPOwizzard
IPOwizzard Dec. 5 at 2:56 PM
$NNVC go bisch
0 · Reply
NoHandOutz
NoHandOutz Dec. 5 at 1:57 PM
$NNVC don't forget its a biotech and these tend to move in cycles with trials and funding periods. Looks like the next bull cycle could be starting.
0 · Reply
NoHandOutz
NoHandOutz Dec. 5 at 1:56 PM
$NNVC "The immediate study, which could start by late CY25 or early in CY26," https://www.biospace.com/press-releases/nanoviricides-dual-track-clinical-strategy-explained-by-a-research-report-broad-spectrum-antiviral-nv-387-at-phase-ii-clinical-trial-stage-for-mpox-and-also-for-acute-respiratory-infections-of-all-viruses
0 · Reply
CameoBrien
CameoBrien Dec. 5 at 1:33 PM
$NNVC bounce
0 · Reply
NoHandOutz
NoHandOutz Dec. 5 at 1:13 PM
$NNVC Looks bottomed. Super quiet now.
0 · Reply
Latest News on NNVC
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

Dec 1, 2025, 8:30 AM EST - 5 days ago

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

Nov 17, 2025, 8:30 AM EST - 19 days ago

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

Nov 14, 2025, 8:30 AM EST - 22 days ago

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 12, 2025, 5:01 PM EST - 24 days ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 11, 2025, 8:30 AM EST - 25 days ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Nov 10, 2025, 8:30 AM EST - 26 days ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

Nov 5, 2025, 8:30 AM EST - 4 weeks ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Nov 3, 2025, 8:30 AM EST - 4 weeks ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Oct 29, 2025, 8:45 AM EDT - 5 weeks ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Oct 27, 2025, 8:45 AM EDT - 5 weeks ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Oct 22, 2025, 8:45 AM EDT - 6 weeks ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Oct 20, 2025, 8:45 AM EDT - 6 weeks ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Oct 15, 2025, 8:45 AM EDT - 7 weeks ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

NanoViricides, Inc. Has Filed its Annual Report

Sep 30, 2025, 8:45 AM EDT - 2 months ago

NanoViricides, Inc. Has Filed its Annual Report

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 11, 2025, 8:30 AM EDT - 3 months ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 3 months ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Aug 18, 2025, 8:30 AM EDT - 3 months ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 30, 2025, 8:30 AM EDT - 4 months ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 23, 2025, 8:30 AM EDT - 4 months ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 21, 2025, 6:30 AM EDT - 4 months ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 5 months ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 18, 2025, 6:30 AM EDT - 6 months ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

NanoViricides Measles Drug Development Animal Study is Imminent

Jun 4, 2025, 6:55 AM EDT - 6 months ago

NanoViricides Measles Drug Development Animal Study is Imminent

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 28, 2025, 6:30 AM EDT - 6 months ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 22, 2025, 6:30 AM EDT - 7 months ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 14, 2025, 6:30 AM EDT - 7 months ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

May 5, 2025, 6:30 AM EDT - 7 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 29, 2025, 6:30 AM EDT - 7 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Apr 14, 2025, 6:30 AM EDT - 8 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 11, 2025, 6:30 AM EDT - 9 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Mar 4, 2025, 6:30 AM EST - 9 months ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 19, 2025, 6:30 AM EST - 10 months ago

NanoViricides, Inc. Has Filed its Quarterly Report

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Feb 11, 2025, 6:30 AM EST - 10 months ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 29, 2025, 6:30 AM EST - 11 months ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 27, 2025, 6:30 AM EST - 11 months ago

NanoViricides Engages CRO for Phase II Clinical Trial

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 13, 2025, 6:30 AM EST - 11 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Jan 8, 2025, 6:30 AM EST - 11 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Dec 23, 2024, 6:30 AM EST - 1 year ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Nov 4, 2024, 12:00 AM EST - 1 year ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 22, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Oct 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Sep 26, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Aug 26, 2024, 7:30 AM EDT - 1 year ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Aug 19, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Aug 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

Aug 1, 2024, 6:30 AM EDT - 1 year ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

Love1010
Love1010 Dec. 6 at 1:43 PM
$NNVC look at all the new pumpers out here! Beware! They're trying to sell shares off to you!
0 · Reply
IPOwizzard
IPOwizzard Dec. 5 at 8:03 PM
$NNVC nom
0 · Reply
CameoBrien
CameoBrien Dec. 5 at 5:58 PM
$NNVC still upside
0 · Reply
CameoBrien
CameoBrien Dec. 5 at 3:44 PM
$NNVC bam
0 · Reply
NoHandOutz
NoHandOutz Dec. 5 at 3:09 PM
$NNVC give it some time. Big boys scaling
0 · Reply
IPOwizzard
IPOwizzard Dec. 5 at 2:56 PM
$NNVC go bisch
0 · Reply
NoHandOutz
NoHandOutz Dec. 5 at 1:57 PM
$NNVC don't forget its a biotech and these tend to move in cycles with trials and funding periods. Looks like the next bull cycle could be starting.
0 · Reply
NoHandOutz
NoHandOutz Dec. 5 at 1:56 PM
$NNVC "The immediate study, which could start by late CY25 or early in CY26," https://www.biospace.com/press-releases/nanoviricides-dual-track-clinical-strategy-explained-by-a-research-report-broad-spectrum-antiviral-nv-387-at-phase-ii-clinical-trial-stage-for-mpox-and-also-for-acute-respiratory-infections-of-all-viruses
0 · Reply
CameoBrien
CameoBrien Dec. 5 at 1:33 PM
$NNVC bounce
0 · Reply
NoHandOutz
NoHandOutz Dec. 5 at 1:13 PM
$NNVC Looks bottomed. Super quiet now.
0 · Reply
CameoBrien
CameoBrien Dec. 5 at 11:50 AM
$NNVC ready?
0 · Reply
CameoBrien
CameoBrien Dec. 2 at 9:49 PM
$NNVC 👀
0 · Reply
Love1010
Love1010 Dec. 1 at 3:56 PM
$NNVC never fight me on this stock...they all have lost big!
0 · Reply
Love1010
Love1010 Dec. 1 at 3:53 PM
$NNVC blah, blah, blah....it's going under $1. Not 90% sure ...100+% sure!!!!!! Don't mess with my calls on this one.
0 · Reply
drkazmd65
drkazmd65 Dec. 1 at 2:33 PM
$NNVC - Another tiny step forward?
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 1 at 1:31 PM
$NNVC NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
0 · Reply
STRAYNUT
STRAYNUT Nov. 25 at 10:46 PM
$NNVC Short Interest (11/14/25) Shares Sold Short 227,743 Change from Last 94.34% Percent of Float 1.31% https://www.wsj.com/market-data/quotes/NNVC
0 · Reply
Love1010
Love1010 Nov. 22 at 1:25 PM
$NNVC it doesn't matter what @STRAYNUT says, this is going under a $1.
0 · Reply
STRAYNUT
STRAYNUT Nov. 22 at 8:45 AM
$NNVC The invested capital of NanoViricides is 156.1 million, the current market value of Nano is roughly $23 million, which is LESS than the appraised value of the lab if sold separately, meaning the entire value of this priceless NV-387 therapeutic technology, 30 years in the making is ZERO. NONSENSE! Let that sink in, I'll wait!
0 · Reply
STRAYNUT
STRAYNUT Nov. 20 at 10:39 PM
$NNVC NV-387, A Broad-Spectrum Antiviral Presenting A Revolutionary Strategy for Viral Infections https://www.nanoviricides.com/files/Presentations/2025-11-08%20NanoViricides%20-%20Annual%20Shareholder%20Meeting%20Presentation.key.pdf
0 · Reply
Love1010
Love1010 Nov. 20 at 6:57 PM
$NNVC crap is crap
0 · Reply
Love1010
Love1010 Nov. 20 at 1:22 PM
$NNVC lower lows and lower highers for 20 years!
0 · Reply